You are here: Industry Insights > combination

News List

First Patient Dosed in Trial of Sitravatinib in Combination with Tislelizumab americanpharmaceuticalreview
November 13, 2018
First Patient Dosed in Trial of Sitravatinib in Combination with Tislelizumab
Combination chemotherapy may significantly improve treatment for glioblastoma europeanpharmaceuticalreview
January 24, 2018
Addition of hydroxyurea to current chemotherapy significantly improved survival in animal models of glioblastoma…
BMS and Clovis Oncology announce a broad clinical collaboration to evaluate combination of Opdivo an cphi-online
August 01, 2017
Pivotal Phase III trials planned for 2017 will evaluate Rubraca + Opdivo, Rubraca as monotherapy, and Opdivo as monotherapy in first line maintenance treatment for advanced ovarian and advanced triple-negative breast cancers.
EMA validates Gilead Sciences’ marketing application for BIC/FTC/TAF combination pharmaceutical-technology
July 17, 2017
US biopharmaceutical company Gilead Sciences’ marketing authorisation application (MAA) for a fixed-dose drug combination to treat HIV-1 infection in adults has been fully validated and is currently under evaluation by the European Medicines Agency (EMA).
Combination therapy shown to shrink tumours in many patients whose cancer has spread to the brain cphi-online
June 06, 2017
Combination of nivolumab plus ipilimumab can fundamentally change survival expectations.
BMS and Apexigen to Evaluate Opdivo in Combination with APX005M in Advanced Solid Tumors americanpharmaceuticalreview
April 12, 2017
Bristol-Myers Squibb Company and Apexigen, Inc. announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Apexigen’s APX005M in patients with advanced solid tumors.
Novartis’ lung cancer drug combination receives EU approval europeanpharmaceuticalreview
April 06, 2017
The European Commission has approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer (NSCLC).
BMS and Incyte to advance the combination of Opdivo and Epacadostat into first-line registrational t cphi-online
April 05, 2017
Companies to initiate Phase III registrational trials in first-line NSCLC across the spectrum of PD-L1 expression and first-line head and neck cancer in 2017.
Fixed dose combination of drugs versus single-drug formulations to treat tuberculosis europeanpharmaceuticalreview
March 21, 2017
A research team from Spain has prepared a Cochrane systematic review that explores the efficacy, safety, and adherence to fixed-dose combinations (FDCs) of drugs versus single-drug formulations to treat people who are newly diagnosed with tuberculosis (TB
Afatinib to be evaluated in combination with pembrolizumab in new trial for patients with SqCC of th cphi-online
February 13, 2017
Boehringer Ingelheim to conduct trial in collaboration with a subsidiary of Merck (MSD).

Previous page 1 2 Next page